Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Three-year data from Biomarin’s haemophilia A gene therapy fail to quash concerns about durability, but the company insists that the results are good enough to file on.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.